• Wondering if Baxter International at around US$18.16 is a bargain or a value trap? This article breaks down what that price really implies for you.
• The stock has been choppy, with a 6.1% return over 30 days and returns of 2.9% over 7 days, 6.9% year to date, 39.1% over 1 year, 59.2% over 3 years, and 76.5% over 5 years.
• Recent share price moves come against a backdrop of ongoing scrutiny of medical equipment companies and how investors view their long term prospects. For Baxter, that context has kept questions about risk and future value firmly in focus.
• Right now, Baxter scores a 5 out of 6 on Simply Wall St's valuation checks. Next, you will see how different methods such as discounted cash flows and market multiples approach that number, followed by a way to go one step further in understanding what it could mean for your own decision making.

Approach 1: Baxter International Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. It is essentially asking what Baxter International’s future cash generation might be worth in today’s dollars.

For Baxter, the model used is a 2 Stage Free Cash Flow to Equity approach, starting from last twelve months free cash flow of about $350.5 million. Analyst inputs and Simply Wall St extrapolations produce a set of annual free cash flow projections through to 2035, with a forecast of $926 million in 2028 and discounted values provided for each year.

When all those discounted cash flows are added together, the model arrives at an estimated intrinsic value of US$27.58 per share. Against a current share price of roughly US$18.16, that implies the stock is trading at a 34.1% discount to this DCF estimate, which points to potential undervaluation based solely on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 34.1%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: Baxter International Price vs Sales

For companies where earnings can be distorted by one off items, the P/S ratio is often a useful cross check, because it compares what you pay for each dollar of revenue rather than each dollar of earnings.

The level of P/S investors are usually comfortable with often reflects expectations for future growth and the risk they see in those revenues. Higher expected growth or lower perceived risk can justify a higher P/S, while slower growth or higher risk tends to be linked with a lower multiple.

Baxter International currently trades on a P/S of 0.83x, compared with the Medical Equipment industry average of 2.96x and a peer average of 5.13x. Simply Wall St’s Fair Ratio for Baxter, at 1.13x, is a proprietary estimate of the P/S that might be reasonable given factors such as earnings growth, margins, market cap, industry and specific risks. This Fair Ratio can be more tailored than a simple comparison with peers or the broad industry, because it adjusts for company specific characteristics rather than assuming all firms deserve the same multiple. On this basis, Baxter’s actual P/S of 0.83x is below the Fair Ratio of 1.13x, which indicates potential undervaluation using this metric alone.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Baxter International Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple story you attach to your numbers, where you spell out what you think Baxter International’s future revenue, earnings, margins and fair value should look like, then compare that fair value with today’s price to decide whether it looks attractive or stretched for you personally.

On Simply Wall St’s Community page, Narratives make this easy by linking a company’s story directly to a financial forecast that updates when new information such as earnings, news or guidance comes in, so your view does not stay static while the facts change.

For Baxter International, one investor might build a more cautious Narrative that lines up with a fair value near US$17.00, assuming modest 1.9% annual revenue growth, margins near 6.3% and a P/E of 15.7x by 2029. Another might prefer an optimistic Narrative that supports a fair value closer to US$33.38, with 2.6% revenue growth, margins around 6.1% and a P/E of 31.3x. By comparing each fair value to the current share price, you can quickly see which story, if any, matches your own expectations.

For Baxter International, however, we will make it really easy for you with previews of two leading Baxter International Narratives:

Fair value in this bullish narrative is US$33.38 per share.

At the last close of US$18.16, that is about 45.6% below this fair value estimate.

Revenue growth assumption: 2.62% a year.

• Assumes new products, partnerships and operational changes support margin expansion and revenue growth above what many analysts currently factor in.
• Leans on ageing populations, chronic disease trends and emerging markets exposure to support steadier long term demand for Baxter's hospital and surgical products.
• Requires confidence that management can manage post divestiture costs, handle regulatory scrutiny and still reach earnings of about US$740.3 million by 2029 on a P/E of 31.3x.

Fair value in this bearish narrative is US$17.00 per share.

At the last close of US$18.16, that is about 6.8% above this fair value estimate.

Revenue growth assumption: 1.89% a year.

• Bakes in ongoing cost pressure on hospital systems, more preventive and at home care, and tougher competition, which all weigh on demand and pricing for Baxter's core hospital products.
• Highlights that portfolio reshaping, divestitures and operational disruptions could reduce scale benefits and keep a lid on margins despite some new product activity.
• Assumes Baxter reaches earnings of about US$752.8 million by 2029 but on a lower P/E of 15.7x, keeping fair value closer to the high teens and indicating a more balanced risk reward profile at current prices.

These two narratives bracket a wide fair value range, from about US$17.00 to US$33.38. Your own view on Baxter will likely sit somewhere between them, depending on how much weight you give to execution risks, product rollouts and long term demand trends.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Baxter International on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.